Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung.
Article content
'As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives,' said Maria Zannes, President and CEO of bioAffinity Technologies.
Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking.
Article content
'We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science,' Ms. Zannes said. 'Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics.'
Article content
The Canadian patent (Patent No. 3,136,245) – titled 'System and Method for Determining Lung Health' – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum.
Article content
CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters.
Article content
About CyPath® Lung
Article content
CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.
Article content
About bioAffinity Technologies, Inc.
Article content
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Article content
Forward-Looking Statements
Article content
Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
bioAffinity Technologies
Article content
Article content
Julie Anne Overton
Article content
Article content
Director of Communications
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
21 minutes ago
- National Post
Canada's homebuilding industry feeling strain of U.S. tariffs on costs, supply chain
Article content 'They're taking advantage of the availability of acquiring it and then having it available for the future, which then increases the overhead because you're holding on to that material, rather than acquiring it when you need it,' Shindruk said. Article content With early concerns about the effects of the trade war, Greater Toronto Area-based Altree Developments had forecast a three to five per cent hit to its overall budget, said the company's president and CEO, Zev Mandelbaum. Article content That figure has since decreased due to more Canadian material being available than first anticipated, said Mandelbaum. But he said the roller-coaster of tariff developments — from the latest threat of additional levies to hope that ongoing negotiations will soon lead to a new trade deal — has made it 'impossible' to plan ahead. Article content He added his company has seen a far greater impact on the revenue side of the business over the past six months, as economic uncertainty drove down buyer demand. Article content 'It was more the fear of just … economic instability in Canada that stopped house buying and stopped people from wanting to invest, whether it be locals looking for homes or foreigners looking to invest in the country,' he said. Article content Article content 'That alienation caused us to have less sales, and because of that, that put even more pressure on construction costs.' Article content In its housing forecast for the year, published in February, Canada Mortgage and Housing Corp. predicted a trade war between Canada and the U.S. — combined with other factors such as reduced immigration targets — would likely slow the economy and limit housing activity. Article content The national housing agency had also said Canada was set for a slowdown in housing starts over the next three years — despite remaining above the 10-year average — due to fewer condominiums being built, as investor interest lags and demand from young families wanes. Article content As of June, year-to-date housing starts totalled 114,411 across regions with a population of 10,000 or greater, up four per cent from the first half of 2024. Article content Article content Despite that boost in new construction, a regional analysis shows provinces with industries more exposed to tariffs are experiencing a slowdown, said CMHC chief economist Mathieu Laberge. He noted Ontario's housing starts have dropped around 26 per cent to date year-over-year, while B.C. has seen an eight per cent decline. Article content Article content In Ontario, five of the 10 most tariff-impacted cities also recorded an increase in mortgage arrears during the spring. Laberge said the trade war, or associated macroeconomic factors, likely prompted layoffs in those regions, which meant people couldn't pay their mortgage. Article content He said he expects that will eventually translate to a lower number of homes being built. 'This is a slow filter through, but it's a real one. We see it happening — although maybe not in the housing starts or resales yet,' Laberge said. Article content Lee said the industry is already noticing those effects. Article content 'The big problem now is we're just not getting the kind of starts we need and there's a lot of concern in the industry now,' Lee said. Article content Before tariffs, he said some regions, such as Atlantic Canada and the Prairies, had started to see housing starts rebound from a national lull that was fuelled by previously high interest rates. Other provinces, such as Ontario and B.C. — where houses remain the most expensive — hadn't yet reached similar levels of new construction.
CTV News
an hour ago
- CTV News
‘Fantastic Four: First Steps' scores Marvel's first $100 million box office opening of 2025
This image released by Disney shows Pedro Pascal in a scene from "The Fantastic Four: First Steps." (Marvel/Disney via AP) LOS ANGELES — Marvel's first family has finally found box office gold. 'The Fantastic Four: First Steps,' the first film about the superheroes made under the guidance of Kevin Feige and the Walt Disney Co., earned $118 million in its first weekend in 4,125 North American theaters, according to studio estimates Sunday. That makes it the fourth biggest opening of the year, behind 'A Minecraft Movie,' 'Lilo & Stitch' and 'Superman,' and the biggest Marvel opening since 'Deadpool & Wolverine' grossed $211 million out of the gate last summer. Internationally, 'Fantastic Four' made $100 million from 52 territories, adding up to a $218 million worldwide debut. The numbers were within the range the studio was expecting. The film arrived in the wake of another big superhero reboot, James Gunn's 'Superman,' which opened three weekends ago and has already crossed $500 million globally. That film, from the other main player in comic book films, DC Studios, took second place with $24.9 million domestically. 'First Steps' is the latest attempt at bringing the superhuman family to the big screen, following lackluster performances for other versions. The film, based on the original Marvel comics, is set during the 1960s in a retro-futuristic world led by the Fantastic Four, a family of astronauts-turned-superhuman from exposure to cosmic rays during a space mission. The family is made up of Reed Richards (Pedro Pascal), who can stretch his body to incredible lengths; Sue Storm (Vanessa Kirby), who can render herself invisible; Johnny Storm (Joseph Quinn), who transforms into a fiery human torch; and Ben Grimm (Ebon Moss-Bachrach), who possesses tremendous superhuman strength with his stone-like flesh. The movie takes place four years after the family gained powers, during which Reed's inventions have transformed technology, and Sue's diplomacy has led to global peace. Both audiences and critics responded positively to the film, which currently has an 88% on Rotten Tomatoes and promising exit poll responses from opening weekend ticket buyers. An estimated 46 per cent of audiences chose to see it on premium screens, including IMAX and other large formats. The once towering Marvel is working to rebuild audience enthusiasm for its films and characters. Its two previous offerings this year did not reach the cosmic box office heights of 'Deadpool & Wolverine,' which made over $1.3 billion, or those of the 'Avengers'-era. But critically, the films have been on an upswing since the poorly reviewed 'Captain America: Brave New World,' which ultimately grossed $415 million worldwide. 'Thunderbolts,' which jumpstarted the summer movie season, was better received critically but financially is capping out at just over $382 million globally. Like Deadpool and Wolverine, the Fantastic Four characters had been under the banner of 20th Century Fox for years. The studio produced two critically loathed, but decently profitable attempts in the mid-2000s with future Captain America Chris Evans as the Human Torch. In 2015, it tried again (unsuccessfully) with Michael B. Jordan and Miles Teller. They got another chance after Disney's $71 billion acquisition of Fox's entertainment assets in 2019. Top 10 movies by domestic box office With final domestic figures being released Monday, this list factors in the estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore: 1. 'The Fantastic Four: First Steps,' $118 million. 2. 'Superman,' $24.9 million. 3. 'Jurassic World Rebirth,' $13 million. 4. 'F1: The Movie,' $6.2 million. 5. 'Smurfs,' $5.4 million. 6. 'I Know What You Did Last Summer,' $5.1 million. 7. 'How to Train Your Dragon,' $2.8 million. 8. 'Eddington,' $1.7 million. 9. 'Saiyaara,' $1.3 million. 10. 'Oh, Hi!,' $1.1 million. Lindsey Bahr And Itzel Luna, The Associated Press
Vancouver Sun
an hour ago
- Vancouver Sun
Trump's tariff threats against Canada face legal hurdles ahead of August deadline
Donald Trump's plan to realign global trade faces its latest legal barrier this week in a federal appeals court — and Canada is bracing for the U.S. president to follow through on his threat to impose higher tariffs. While Trump set an Aug. 1 deadline for countries to make trade deals with the United States, the president's ultimatum has so far resulted in only a handful of frameworks for trade agreements. Deals have been announced for Japan, Vietnam, Indonesia, the Philippines and the United Kingdom — but Trump indicated last week that an agreement with Canada is far from complete. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. 'We don't have a deal with Canada, we haven't been focused on it,' Trump told reporters Friday. Trump sent a letter to Prime Minister Mark Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by the deadline. The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade. Canadian officials have also downplayed expectations of a new economic and security agreement materializing by Friday. 'We'll use all the time that's necessary,' Carney said last week. Countries around the world will also be watching as Trump's use of a national security statute to hit nations with tariffs faces scrutiny in the United States Court of Appeals for the Federal Circuit. The U.S. Court of International Trade ruled in May that Trump does not have the authority to wield tariffs on nearly every country through the use of the International Economic Emergency Powers Act of 1977. The act, usually referred to by the acronym IEEPA, gives the U.S. president authority to control economic transactions after declaring an emergency. No previous president had ever used it for tariffs and the U.S. Constitution gives power over taxes and tariffs to Congress. The Trump administration quickly appealed the lower court's ruling on the so-called 'Liberation Day' and fentanyl-related tariffs and arguments are set to be heard in the appeal court on Thursday. The hearing combines two different cases that were pushing against Trump's tariffs. One involves five American small businesses arguing specifically against Trump's worldwide tariffs, and the other came from 12 states pushing back on both the 'Liberation Day' duties and the fentanyl-related tariffs George Mason University law professor Ilya Somin called Trump's tariff actions a 'massive power grab.' Somin, along with the Liberty Justice Center, is representing the American small businesses. 'We are hopeful — we can't know for sure obviously — we are hopeful that we will continue to prevail in court,' Somin said. Somin said they are arguing that IEEPA does not 'give the president the power to impose any tariff he wants, on any nation, for any reason, for as long as he wants, whenever he feels like it.' He added that 'the law also says there must be an emergency and an unusual and extraordinary threat to American security or the economy' — and neither the flow of fentanyl from Canada nor a trade deficit meet that definition. U.S. government data shows a minuscule volume of fentanyl is seized at the northern border. The White House has said the Trump administration is legally using powers granted to the executive branch by the Constitution and Congress to address America's 'national emergencies of persistent goods trade deficits and drug trafficking.' There have been 18 amicus briefs — a legal submission from a group that's not party to the action — filed in support of the small businesses and states pushing against Trump's tariffs. Two were filed in support of the Trump administration's actions. Brent Skorup, a legal fellow at the Washington-based Cato Institute, said the Trump administration is taking a vague statute and claiming powers never deployed by a president before. The Cato Institute submitted a brief that argued 'the Constitution specifies that Congress has the power to set tariffs and duties.' Skorup said there are serious issues with the Trump administration's interpretation of IEEPA. 'We don't want power consolidated into a single king or president,' he said. It's expected the appeals court will expedite its ruling. Even if it rules against the duties, however, they may not be immediately lifted. White House Press Secretary Karoline Leavitt has said the Supreme Court should 'put an end to this.' There are at least eight lawsuits challenging the tariffs. Canada is also being hit with tariffs on steel, aluminum and automobiles. Trump used different powers under the Trade Expansion Act of 1962 to enact those duties. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here .
